Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/No renal benefit from stopping ACE inhibitors and ARBs
Renal · ACEARB-RENAL-03 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
The question is whether stopping ACE inhibitors or ARBs in people with advanced kidney disease actually helps their kidneys. A trial built specifically to test this [5] randomly assigned patients to stop or keep taking these drugs and found no meaningful difference in kidney function after three years, and a follow-up analysis [13] found stopping neither drug type slowed kidney decline. Several large real-world studies tracking patients who stopped versus continued [9][8][23][21] consistently found stopping was either no better or worse, never better, for the kidneys. The one study pointing the other way [3] was small, had no comparison group, and simply tracked patients before and after stopping. The panel treated that early signal as the idea the trial was designed to check and did not confirm. The main cautions are that the trial was unblinded and that its hardest kidney endpoint did not reach a clear answer.
The dedicated randomized trial [5] found a between-group eGFR difference at 3 years of -0.7 (95% CI -2.5 to 1.0; P=0.42), with ESKD or renal-replacement therapy numerically more common after stopping (hazard ratio 1.28; 95% CI 0.99 to 1.65). The companion analysis [13] reported that neither discontinuing ACEi nor ARB slowed eGFR decline. Independent cohorts in advanced CKD point the same way: discontinuation was associated with higher ESKD risk in Hong Kong type 2 diabetes patients (HR 1.30; 95% CI 1.17-1.43) [9], in US veterans [8], and after an acute eGFR decline (ESKD HR 1.74; 95% CI 1.28-2.38) [21]; the Pennsylvania cohort [23] found higher mortality on stopping with no significant ESKD difference (HR 1.19; 95% CI 0.86-1.65). The sole contrary result, an uncontrolled before-after study of 52 patients [3], reported eGFR rising after discontinuation (to 26.6 from a low baseline; p=0.0001). The contested point: The division is between the single small uncontrolled study [3], which saw kidney function improve after stopping, and the randomized trial [5] plus every larger cohort, which saw no improvement or harm. A secondary tension sits inside the trial itself: it was powered for the eGFR surrogate, while its hard ESKD endpoint was numerically worse on stopping but statistically inconclusive (HR 1.28; 95% CI 0.99 to 1.65) [5].
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal trial [5] is open-label, so the continuation/discontinuation groups are unblinded; the primary eGFR endpoint is objective (mitigating), but clinician-driven decisions (e.g. RRT initiation) are susceptible to bias.
Only one RCT (N=411) carries the claim; it was powered for eGFR, and the hard renal outcome ESKD/RRT was numerically worse with stopping but statistically inconclusive (HR 1.28, 95% CI 0.99-1.65), so the definitive-grade renal evidence rests on a surrogate.
Where it remains uncertain. The trial's hard renal endpoint (ESKD/RRT) was numerically worse on stopping but inconclusive (HR 1.28; 95% CI 0.99 to 1.65) [5], so the non-improvement rests on the eGFR surrogate; the only contrary signal is the uncontrolled N=52 study [3].
Aleatory
The trial's ESKD/RRT hazard ratio spans no effect (HR 1.28; 95% CI 0.99 to 1.65) [5], so sampling variability alone leaves the hard renal outcome unresolved.
Epistemic
Only one RCT (N=411) [5] directly tests stopping versus continuing; no independent trial in the corpus replicates it.
Inferential
Non-improvement rests on the eGFR endpoint [5][13]; inferring from eGFR to hard outcomes like ESKD is a step the inconclusive ESKD estimate does not close.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT directly testing the claim in advanced CKD (eGFR<30): stopping did not improve the primary renal endpoint.
“Among patients with advanced and progressive chronic kidney disease, the discontinuation of RAS inhibitors was not associated with a significant between-group difference in the long-term rate of decrease in the eGFR.”
Panel auditInternal validity: high · scope of inference: Patients with advanced and progressive CKD (eGFR <30) randomized to stop or continue RAS inhibitors.Key limitations: open-label · modest sample · ESKD trend not significant (HR 1.28)
Large US cohort corroborates that stopping does not improve and is associated with worse renal outcomes.
“ACEI/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD.”
Panel auditInternal validity: medium · scope of inference: Predominantly male US veterans with non-dialysis CKD stages 3 and 4.Key limitations: observational confounding by indication · stage 3 not advanced · mostly male veterans
Advanced CKD T2D cohort: stopping raised ESKD risk, consistent with no renal improvement.
“Discontinued-ACEi/ARBs use was associated with higher risk of MACE (HR = 1.27, 95% CI: 1.08-1.49), heart failure (HR = 1.85, 95% CI: 1.53-2.25) and ESKD (HR = 1.30, 95% CI: 1.17-1.43)”
Panel auditInternal validity: medium · scope of inference: Chinese patients in Hong Kong with type 2 diabetes reaching eGFR <30.Key limitations: observational confounding · diabetes-only population · single-region cohort
The dissenting uncontrolled signal suggesting improvement after stopping, which the subsequent RCT [5] did not confirm.
“12 months after discontinuation of ACEi/ARB eGFR increased significantly to 26.6 ± 2.2 ml/min/ 1.73 m(2) (p = 0.0001)”
Panel auditInternal validity: low · scope of inference: Elderly advanced CKD patients approaching renal replacement at one low-clearance clinic.Key limitations: no control group · small sample · surrogate eGFR outcome · regression to mean possible
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A purpose-built RCT with an objective prespecified renal endpoint, corroborated by multiple large independent cohorts against a single tiny uncontrolled dissent, carries the non-improvement claim, with the open-label design and inconclusive RCT ESKD estimate placing it at the floor of Established.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Hard renal endpoint remains underpowered. The non-improvement conclusion rests on eGFR; the trial's ESKD/RRT estimate crossed no effect (HR 1.28; 95% CI 0.99 to 1.65) [5], leaving the hardest outcome open. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: An adequately powered RCT or pooled individual-patient analysis with ESKD/RRT as the primary endpoint in eGFR<30 CKD.
Open question: Does stopping ACEi/ARBs in advanced CKD change the risk of end-stage kidney disease, as opposed to the eGFR trajectory? Why it is still open: The trial's ESKD estimate was numerically worse but statistically inconclusive (HR 1.28; 95% CI 0.99 to 1.65) [5].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19